Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates GlobeNewswire November 13, 2025 Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate that Utilizes Less-intensive or No Conditioning, Enabling Broad Patient Accessibility First Systemic Sclerosis […]